Yoshikazu Inoue

List of Publications by Year in descending order

132 papers	20,921 citations	41344 49 h-index	14208 128 g-index
134 all docs	134 docs citations	134 times ranked	13581 citing authors

#	Article	IF	Citations
1	Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2071-2082.	27.0	3,351
2	An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 733-748.	5.6	3,134
3	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	5.6	2,678
4	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine, 2019, 381, 1718-1727.	27.0	1,338
5	Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis. New England Journal of Medicine, 2011, 364, 1595-1606.	27.0	922
6	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2022, 205, e18-e47.	5.6	780
7	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respiratory Medicine,the, 2018, 6, 138-153.	10.7	739
8	The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology, 2020, 296, 172-180.	7.3	721
9	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	5.6	508
10	Characteristics of a Large Cohort of Patients with Autoimmune Pulmonary Alveolar Proteinosis in Japan. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 752-762.	5.6	391
11	Nintedanib in patients with progressive fibrosing interstitial lung diseasesâ€"subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respiratory Medicine,the, 2020, 8, 453-460.	10.7	331
12	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respiratory Medicine,the, 2020, 8, 726-737.	10.7	279
13	KL-6, a Mucin-like Glycoprotein, in Bronchoalveolar Lavage Fluid from Patients with Interstitial Lung Disease. The American Review of Respiratory Disease, 1993, 148, 637-642.	2.9	254
14	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 748-761.	5.6	236
15	Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 178-185.	5.6	209
16	Serological Diagnosis of Idiopathic Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 658-662.	5.6	199
17	Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangioleiomyomatosis From Other Diseases. Chest, 2010, 138, 674-681.	0.8	188
18	Inhaled Granulocyte/Macrophageâ€"Colony Stimulating Factor as Therapy for Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1345-1354.	5.6	184

#	Article	IF	Citations
19	Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1382-1392.	6.7	171
20	Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respiratory Medicine,the, 2013, 1, 445-452.	10.7	159
21	Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1337-1348.	5.6	159
22	KL-6, a Human MUC1 Mucin, Is Chemotactic for Human Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 1997, 17, 501-507.	2.9	156
23	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respiratory Research, 2017, 4, e000212.	3.0	151
24	Pulmonary Epithelial Cell Injury and Alveolarâ€“Capillary Permeability in Berylliosis. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 109-115.	5.6	122
25	Diagnostic Potential of Serum VEGF-D for Lymphangioleiomyomatosis. New England Journal of Medicine, 2008, 358, 199-200.	27.0	122
26	Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respiratory Research, 2019, 6, e000397.	3.0	121
27	Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. Lancet Respiratory Medicine,the, 2018, 6, 554-565.	10.7	119
28	Basic Fibroblast Growth Factor and Its Receptors in Idiopathic Pulmonary Fibrosis and Lymphangioleiomyomatosis. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 765-773.	5.6	112
29	Granulocyte-Macrophage Colonyâ€“Stimulating Factor and Lung Immunity in Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1142-1149.	5.6	104
30	Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. New England Journal of Medicine, 2019, 381, 923-932.	27.0	103
31	The epidemiology of lymphangioleiomyomatosis in Japan: A nationwide cross-sectional study of presenting features and prognostic factors. Respirology, 2007, 12, 523-530.	2.3	100
32	Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. Orphanet Journal of Rare Diseases, 2016, 11, 115.	2.7	100
33	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	5.6	90
34	Pulmonary alveolar proteinosis. Clinics in Chest Medicine, 2004, 25, 593-613.	2.1	83
35	Design of the INPULSISâ„¢ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2014, 108, 1023-1030.	2.9	82
36	Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. Journal of Immunological Methods, 2014, 402, 57-70.	1.4	80

#	Article	IF	Citations
37	Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest, 2020, 158, 646-659.	0.8	79
38	Morphometric Analysis of Insulin-like Growth Factor-I Localization in Lung Tissues of Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1626-1635.	5.6	75
39	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	6.7	75
40	Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respiratory Investigation, 2018, 56, 268-291.	1.8	72
41	Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia. Thorax, 2011, 66, 61-65.	5.6	71
42	Quantitative CT in Chronic Obstructive Pulmonary Disease: Inspiratory and Expiratory Assessment. American Journal of Roentgenology, 2009, 192, 267-272.	2.2	69
43	All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respiratory Investigation, 2015, 53, 232-241.	1.8	69
44	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine,the, 2019, 7, 771-779.	10.7	65
45	Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. New England Journal of Medicine, 2020, 383, 1635-1644.	27.0	61
46	Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine, 2005, 23, 2132-2135.	3.8	60
47	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	5.6	60
48	Duration of Benefit in Patients With Autoimmune Pulmonary Alveolar Proteinosis After Inhaled Granulocyte-Macrophage Colony-Stimulating Factor Therapy. Chest, 2014, 145, 729-737.	0.8	56
49	Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. European Respiratory Journal, 2019, 53, 1802243.	6.7	56
50	Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1110-1119.	5.6	56
51	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. Radiology, 2021, 298, 550-566.	7.3	53
52	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. Chest, 2021, 159, 1107-1125.	0.8	53
53	Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. BMC Pulmonary Medicine, 2014, 14, 37.	2.0	51
54	Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study. BMC Pulmonary Medicine, 2015, 15, 88.	2.0	47

#	Article	IF	Citations
55	Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. European Respiratory Journal, 2022, 59, 2004538.	6.7	47
56	Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180075.	7.1	45
57	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respiratory Investigation, 2021, 59, 709-740.	1.8	45
58	Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respiratory Investigation, 2014, 52, 136-143.	1.8	43
59	Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis. Annals of the American Thoracic Society, 2016, 13, 1912-1922.	3.2	42
60	DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine, 2006, 24, 1191-1204.	3.8	41
61	Analysis of the MILES cohort reveals determinants of disease progression andÂtreatment response in lymphangioleiomyomatosis. European Respiratory Journal, 2019, 53, 1802066.	6.7	41
62	Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF. Respiratory Medicine, 2004, 98, 1227-1230.	2.9	39
63	Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia. Respirology, 2016, 21, 1431-1437.	2.3	39
64	Epidemiological and clinical features of idiopathic pulmonary alveolar proteinosis in Japan. Respirology, 2006, 11, S55-S60.	2.3	38
65	Highâ€dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. Respirology, 2017, 22, 1363-1370.	2.3	37
66	Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSISÂ® randomized trials. Respirology, 2017, 22, 750-757.	2.3	37
67	Lung function outcomes in the INPULSISÂ® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 146, 42-48.	2.9	34
68	Mast Cell Basic Fibroblast Growth Factor in Silicosis. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 2026-2034.	5.6	32
69	Subgroup analysis of <scp>A</scp>sian patients in the <scp>INPULSIS</scp>^{Â®} trials of nintedanib in idiopathic pulmonary fibrosis. Respirology, 2016, 21, 1425-1430.	2.3	31
70	Pulmonary Fibrosis on High-Resolution CT of Patients With Pulmonary Alveolar Proteinosis. American Journal of Roentgenology, 2016, 207, 544-551.	2.2	29
71	<scp>CYFRA</scp> 21â€1 as a disease severity marker for autoimmune pulmonary alveolar proteinosis. Respirology, 2014, 19, 246-252.	2.3	28
72	Analysis of systemic lupus erythematosus-related interstitial pneumonia: a retrospective multicentre study. Scientific Reports, 2019, 9, 7355.	3.3	28

#	Article	IF	Citations
73	Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. Nature Communications, 2021, 12, 1032.	12.8	26
74	Utility of expiratory thin-section CT for fibrotic interstitial pneumonia. Acta Radiologica, 2014, 55, 1050-1055.	1.1	24
75	MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. JCI Insight, 2020, 5, .	5.0	24
76	Longâ€term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSISÂ®â€ON. Respirology, 2020, 25, 410-416.	2.3	23
77	Anti-IL-6 Receptor Antibody Causes Less Promotion of Tuberculosis Infection than Anti-TNF- Antibody in Mice. Clinical and Developmental Immunology, 2011, 2011, 1-9.	3.3	21
78	SECRETORY EFFECTS OF VASOACTIVE INTESTINAL POLYPEPTIDE (VIP), ADRENALINE AND CARBACHOL IN ISOLATED LOBULES OF THE RAT PAROTID GLAND . Biomedical Research, 1982, 3, 384-389.	0.9	21
79	Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database. Respiratory Investigation, 2016, 54, 193-200.	1.8	20
80	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.8	19
81	Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients. Respirology, 2018, 23, 331-338.	2.3	18
82	Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. ERJ Open Research, 2020, 6, 00184-2019.	2.6	18
83	Disease severity staging system for idiopathic pulmonary fibrosis in Japan. Respirology, 2017, 22, 1609-1614.	2.3	17
84	Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. Respirology, 2019, 24, 658-666.	2.3	16
85	Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology, 2022, 27, 66-75.	2.3	16
86	Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis. Nature Communications, 2022, 13, 1558.	12.8	16
87	Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology, 2022, 27, 294-300.	2.3	15
88	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	5.6	15
89	Classification of idiopathic interstitial pneumonias using antiâ€“myxovirus resistance-protein 1 autoantibody. Scientific Reports, 2017, 7, 43201.	3.3	14
90	Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. PLoS ONE, 2019, 14, e0212776.	2.5	14

#	Article	IF	Citations
91	High-resolution CT features distinguishing usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis from those with idiopathic pulmonary fibrosis. Japanese Journal of Radiology, 2020, 38, 524-532.	2.4	14
92	Influence of surface light scattering and glistenings of intraocular lenses on visual function 15 to 20 years after surgery. Journal of Cataract and Refractive Surgery, 2018, 44, 219-225.	1.5	13
93	Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases. Current Opinion in Pulmonary Medicine, 2020, 26, 507-517.	2.6	13
94	Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD . International Journal of COPD, 2019, Volume 14, 2993-3002.	2.3	12
95	Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study . International Journal of COPD, 2019, Volume 14, 2979-2991.	2.3	12
96	A Semiquantitative Computed Tomographic Grading System for Evaluating Therapeutic Response in Pulmonary Alveolar Proteinosis. Annals of the American Thoracic Society, 2017, 14, 1403-1411.	3.2	11
97	Light chain (Îºí») ratio of GM-CSF autoantibodies is associated with disease severity in autoimmune pulmonary alveolar proteinosis. Clinical Immunology, 2013, 149, 357-364.	3.2	10
98	Clinical significance of serum anti-granulocyteâ€“macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis. Orphanet Journal of Rare Diseases, 2020, 15, 272.	2.7	9
99	Cytomegalovirus infection during immunosuppressive therapy for diffuse parenchymal lung disease. Respirology, 2013, 18, 117-124.	2.3	7
100	Tracheobronchial lesions in eosinophilic pneumonia. Respiratory Investigation, 2014, 52, 21-27.	1.8	7
101	Validation of a new serum granulocyteâ€“macrophage colony-stimulating factor autoantibody testing kit. ERJ Open Research, 2020, 6, 00259-2019.	2.6	7
102	Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respiratory Medicine, 2021, 187, 106574.	2.9	6
103	Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases. BMJ Open Respiratory Research, 2022, 9, e001167.	3.0	6
104	Autoimmune Pulmonary Alveolar Proteinosis Following Pulmonary Aspergillosis. Internal Medicine, 2015, 54, 3177-3180.	0.7	5
105	Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union. Current Medical Research and Opinion, 2021, 37, 327-339.	1.9	5
106	Diagnostic yield and safety of bronchofiberscopy for pulmonary alveolar proteinosis. Respiratory Investigation, 2021, 59, 757-765.	1.8	5
107	The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2022, 59, 2101790.	6.7	5
108	Enhanced mast cell chymase expression in human idiopathic interstitial pneumonia. International Journal of Molecular Medicine, 2007, , .	4.0	4

#	Article	IF	Citations
109	Comorbid connective tissue diseases and autoantibodies in lymphangioleiomyomatosis: a retrospective cohort study. Orphanet Journal of Rare Diseases, 2018, 13, 182.	2.7	4
110	Autoimmune Pulmonary Alveolar Proteinosis Complicated with Sarcoidosis: the Clinical Course and Serum Levels of Anti-granulocyte-macrophage colony-stimulating Factor Autoantibody. Internal Medicine, 2020, 59, 2539-2546.	0.7	4
111	A mathematical model to predict protein wash out kinetics during whole-lung lavage in autoimmune pulmonary alveolar proteinosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L105-L117.	2.9	3
112	Massive atelectasis by mucoid impaction in an asthma patient during treatment with antiâ€interleukinâ€5 receptor antibody. Respirology Case Reports, 2020, 8, e00599.	0.6	3
113	Seroradiologic prognostic evaluation of acute exacerbation in patients with idiopathic interstitial pneumonia: a retrospective observational study. Journal of Thoracic Disease, 2020, 12, 4132-4147.	1.4	3
114	B cellâ€activating factors in autoimmune pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases, 2021, 16, 115.	2.7	3
115	Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis. Orphanet Journal of Rare Diseases, 2021, 16, 466.	2.7	3
116	Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage: Predictive Role for Acute Exacerbation of Idiopathic Interstitial Pneumonias. Canadian Respiratory Journal, 2021, 2021, 1-9.	1.6	3
117	Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis. Journal of Thoracic Disease, 2022, 14, 278-294.	1.4	3
118	Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework. Advances in Therapy, 2022, 39, 1045-1054.	2.9	3
119	Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1182-1189.	1.9	2
120	Corticosteroids in acute exacerbations of idiopathic interstitial pneumonias: Time to debate â€“ Reply. Respirology, 2018, 23, 546-547.	2.3	2
121	Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. BMJ Open Respiratory Research, 2020, 7, e000558.	3.0	2
122	Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin. BMJ Open Respiratory Research, 2021, 8, e000889.	3.0	2
123	Drug-related pneumonitis with radiographic hypersensitivity pneumonitis pattern: Three case series. Respiratory Medicine Case Reports, 2021, 34, 101498.	0.4	2
124	Lymphangioleiomyomatosis. , 2016, , 1243-1259.e12.		1
125	Blood testing in the diagnosis of pulmonary alveolar proteinosis â€“ Authors' reply. Lancet Respiratory Medicine,the, 2018, 6, e55.	10.7	1
126	Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier. Internal Medicine, 2019, 58, 569-574.	0.7	1

#	Article	IF	Citations
127	Is corticosteroid use truly not associated with improved outcomes in AEâ€IPF?. Respirology, 2020, 25, 659-659.	2.3	1
128	Lymphoplasmacytic lymphoma involving the mediastinum and the lung, followed by amyloidosis: A surgically and genetically proven case. Respiratory Medicine Case Reports, 2020, 31, 101313.	0.4	1
129	Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis. Canadian Respiratory Journal, 2022, 2022, 1-10.	1.6	1
130	Characteristics and prognosis of interstitial pneumonias complicated with pneumomediastinum. Respiratory Investigation, 2020, 58, 262-268.	1.8	0
131	Lymphangioleiomyomatosis. , 2010, , 1496-1515.		0
132	Preventing infection after synthetic expander implantation in patients undergoing breast reconstruction.. , 2022, 8, 42-45.		0